Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Teniposide Combined with Temozolomide

Preclinical

SSun Yat-sen University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Newly Diagnosed GlioblastomaNot yet recruiting

Newly Diagnosed GlioblastomaPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q4 2030

PreclinicalNot yet recruiting

Newly Diagnosed Glioblastoma

NCT07894549

Clinical

Trials by Indication[1]

Newly Diagnosed Glioblastoma1 trial

A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region Unmethylated

Not yet recruiting·SSun Yat-sen University·Preclinical·NCT07894549·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Teniposide Combined with Temozolomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Teniposide Combined with Temozolomide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SSun Yat-sen University

Related News